P7C3 for Health & Longevity

Created on 11/08/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

P7C3 is a laboratory research chemical, not a medicine or supplement, studied for protecting brain cells and slowing age-related decline. It has protected nerve cells, muscle and bone in many animal studies, including a small monkey study, but has never been tested in a person, and no dose is established. How it works is disputed, and its proposed target enzyme is more active in several cancers. (Full Review)

Protocol

No human dose conversion
No human-equivalent dose can be stated
No therapeutic protocol for P7C3 exists; never given to a person in a published study
Animal dose, parent compound
5 mg/kg and above, oral (mice)
Aged rats received 10 mg/kg daily
Single versus split dosing
Once daily
Every published animal regimen; human half-life unmeasured
Time to effect
Cognitive and pathological reversal
1 to 6 months
Continuous treatment in mice; unknown in humans
Preservation of learning and memory in normal aging
2 months
Daily dosing in 18-month-old rats
New neuron formation
Within 7 days
In animals; unknown in humans

Benefits

Contraindications
  • Anyone outside a regulated research protocol
  • People with active or previously treated malignancy
  • People receiving cytotoxic chemotherapy
  • Pregnancy and lactation
  • People with an autoimmune condition on immunosuppressive therapy
Key Interactions
Theoretical (inferred from mechanism)
  • NAMPT inhibitors (FK866, KPT-9274)
  • Nicotinamide and other NAD⁺ precursors (nicotinamide riboside, nicotinamide mononucleotide)
  • Taxane chemotherapy (paclitaxel, docetaxel)
  • Anthracyclines (doxorubicin and daunorubicin)
  • Central nervous system depressants (benzodiazepines, alcohol, and gabapentinoids)
  • CYP3A4 inhibitors and inducers (ketoconazole, rifampicin)
  • Over-the-counter sedating medicines (diphenhydramine, doxylamine)
  • Over-the-counter niacin and nicotinamide products

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Degeneration of nerve-cell projections at higher exposures; stimulating an enzyme overexpressed in malignancy; off-target inhibition of a glycolytic enzyme; suppression of Th17 immune responses; cell death at high concentrations; central depressant effects through GABA signalling

Monitoring

Marker Target Why
Alanine aminotransferase (ALT) 7–56 U/L (standard reference range) Safety check: liver injury
Estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m² (standard reference range) Safety check: kidney clearance and toxicity
Complete blood count with differential Standard laboratory reference ranges by age and sex Safety check: immune and bone marrow effects
Fasting plasma glucose 70–99 mg/dL (standard reference range) Expected to change: lowered in diabetic mice
Plasma phosphorylated tau 217 (p-tau217) No established target; track change from the individual's own baseline Expected to change: only biomarker linked to its effect in an animal study

Cadence: No frequency has been established for this compound; a research setting would follow first-in-human Phase 1 cadence: baseline, then at 2 and 4 weeks, then every 4–12 weeks while exposure continues

Qualitative Assessment

  • Subjective cognitive clarity and recall
  • Mood and anhedonia
  • Daytime sedation
  • Grip and functional strength
  • Any new or unexplained symptom